Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain and Epilepsy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCN3A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (Full-Length Construct) | SCN3A Promise-ORF / Lentivirus Premade Particles. Full-length ORF with native mammalian codon optimization, HEK293 expression validated. Ideal for Patch-Clamp/FLIPR. | View SCN3A Products |
| Antigen (Extracellular Loop) | SCN3A Recombinant Extracellular Loop / Custom Membrane Preparation. High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. | View SCN3A Products |
| Benchmark Ab | Anti-SCN3A Recombinant Antibody, sequence-optimized positive control for extracellular loop binding assays. | View SCN3A Products |
| Validator | SCN3A siRNA Set (3 unique sequences). For knockdown verification and specificity controls in electrophysiology assays. Endotoxin controlled. | View SCN3A Products |
| Mutant Panel | SCN3A DEE Mutant Proteins (Gain-of-function variants). Expressed in HEK293, high purity (>90%), sequence verified. | View SCN3A Products |
| Ortholog Panel | Human/Mouse/Rat/Cyno SCN3A Comparison Set. For cross-species selectivity and toxicity screening. Theoretical MW verified. | View SCN3A Products |
| Related Target: SCN1A | SCN1A (Nav1.1). Nav channel paralog for CNS selectivity counter-screening and functional comparison. | View SCN1A Products |
| Related Target: SCN2A | SCN2A (Nav1.2). CNS sodium channel; evaluate cross-reactivity for CNS-sparing drug design. | View SCN2A Products |
| Related Target: SCN5A | SCN5A (Nav1.5). Cardiac sodium channel; mandatory for off-target toxicity profiling. | View SCN5A Products |
| Related Target: SCN8A | SCN8A (Nav1.6). Central neuron-enriched sodium channel; critical off-target liability assay. | View SCN8A Products |
| Related Target: SCN9A | SCN9A (Nav1.7). Peripheral pain channel; paralog selectivity panel for analgesic development. | View SCN9A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation Preservation (Multi-pass Ion Channel) | Full-Length SCN3A Lentivirus Particles; pseudotyped for high-efficiency transduction. Cell-based assays preserve native topology. |
| Cross-Species Cyno / Mouse / Rat Evaluation | Human / Cyno / Mouse / Rat SCN3A Ortholog ORF Clones & Lentivirus; Sequence verified, species identity confirmed by mass spec. |
| Nav Subfamily Counter-Screening (Off-Target Safety) | SCN1A / SCN2A / SCN5A / SCN8A / SCN9A Homolog Panel Lentivirus & Proteins; Strict sequence verification for paralog selectivity assays. |
| Target Specificity & Knockdown Validation | SCN3A siRNA Set; Sequence-verified, endotoxin-controlled for rescue and specificity experiments. |
| Functional Readout (Electrophysiology / Membrane Potential) | Premade Lentivirus enables rapid generation of SCN3A-stable HEK293 / Neuro-2a lines compatible with patch-clamp and FLIPR. |
| State-Dependent Binding (Resting vs. Inactivated States) | Full-length SCN3A lentivirus preserves native conformational dynamics; supports voltage-dependent patch-clamp studies. |
| Gain-of-Function Mutation Validation (DEE Variants) | Clinical mutant library (missense mutations); high-purity recombinant proteins for binding assays. |
| False Positives in Automated Electrophysiology | Validated siRNA included for specificity checks; sequence-verified knockdown controls. |
Live SCN3A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SCN3A (Nav1.3) therapeutics is intensifying, with major players shifting focus from broad-spectrum sodium channel blockers to state-dependent selective inhibitors and genetic medicines. As first-generation small molecules (e.g., state-dependent inhibitors from Xenon Pharma / Biogen) and investigational antisense oligonucleotides (ASOs) reach early clinical phases for Developmental and Epileptic Encephalopathies (DEE), the next wave of R&D is targeting combination therapies with SCN1A modulators and peripheral pain indications leveraging developmental re-expression patterns. Achieving subtype selectivity over highly homologous Nav1.1, Nav1.2, Nav1.5, Nav1.6, and Nav1.7 remains the paramount challenge, driving demand for counter-screening panels and native conformation cell lines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (State-Dependent Inhibitor) | Ion-channel focused biotechs (Xenon Pharma, Biogen), academic consortia | DEE, Neuropathic Pain | Paralog Selectivity Panel (Need SCN3A vs SCN1A/SCN2A/SCN5A/SCN8A/SCN9A Lentivirus Cell Lines) |
| Antisense Oligonucleotide (ASO) / Gene Modulation | Rare-disease neurology programs | SCN3A-positive Epilepsy, DEE | Target Validation (Need Full-Length SCN3A ORF + siRNA) |
| Emerging Biologic (mAb/Peptide) | Preclinical CNS-penetrant biologics | Refractory CNS Disorders, Peripheral Neuropathy | Conformational Binding (Need Native Cell-Surface SCN3A via Lentivirus) |
| Precision Medicine (Mutation-specific) | Academic Consortia | Genetic DEE Subtypes | Mutant vs. WT protein binding assays; high-purity variant panels |
Technical Note on Assay Design
SCN3A is a complex tetrametric transmembrane ion channel (24 TMDs) requiring proper membrane insertion and auxiliary subunits (β1-β4) for native gating properties. Cell-based assays using lentivirus-mediated stable expression in HEK293 cells co-expressing β-subunits remain the gold standard for pharmacological validation, as truncated ECD-Fc fusions fail to recapitulate voltage-sensor dynamics.